GGrantIndex
← Search

Transgenic and Targeted Mutagenesis Laboratory Shared Resource

$174,816P30FY2018CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

ABSTRACT ? TRANSGENIC AND TARGETED MUTAGENESIS LABORATORY The Transgenic and Targeted Mutagenesis Laboratory (TTML) is a Northwestern University-wide resource dedicated to the generation, import, recovery/rederivation, and cryopreservation of genetically engineered mice. TTML provides Lurie Cancer Center (LCC) members a broad range of services including generation of transgenic, gene edited, and targeted transgenic mouse models via microinjection; gene targeting/editing of embryonic stem (ES) cells; ES cell microinjection into blastocysts to create germline competent chimera; importation and recovery/rederivation of mouse lines from germplasm; and cryopreservation of mouse sperm and embryos. Since the last review, the core has introduced full-scale, start-to-finish mutagenesis capabilities. These changes were necessary to facilitate the development of newly emerging genome engineering technologies such as CRISPR. The TTML team works with LCC members to design customized genetic modification strategies and genotyping assays, and provides confirmed founders to investigators. These new capabilities, in addition to our traditional methods for creating transgenic and ESC derived mutant lines, enable investigators the opportunity to employ overarching approaches to genetic modification mutagenesis through the facility. The TTML facility is essential for the research programs of investigators of the Lurie Cancer Center who use mouse models to study mechanisms underlying malignancy and validate targets for translational projects. It provides the necessary infrastructure that allows the Center?s investigators access to transgenic technology that normally requires expensive microinjection equipment and skilled staff with expertise in microinjection, microsurgeries, embryo manipulation, animal husbandry, ES cell culture, and genome engineering. In addition, TTML staff provide in-house consultation and recurrent guidance on all transgenic-related technologies including CRISPR-mediated genome editing systems, transgenic and targeting vector design, appropriate screening strategies, DNA purification methods, breeding and analysis of founder mice, appropriate methods for importing mouse lines, and cryopreservation options. Since the inclusion of the TTML as a resource within the Lurie Cancer Center in 1995, Center investigators have consistently been the primary group of NU faculty utilizing the TTML, emphasizing its pivotal role in the overall research mission of the LCC.

View original record on NIH RePORTER →